MondegarAI
Sofinnova Investments, Inc.

Q4 2024 · 13F-HR

Sofinnova Investments, Inc.holdings as filed

Filed 2025-02-14 · accession 0001104659-25-013863

$1.37B
Reported value
61
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
632307104NTRANatera Inc$245.4M17.9%1,550,280CommonSOLE
92337R101VERAVera Therapeutics Inc$118.2M8.61%2,793,987CommonSOLE
375558103GILDGilead Sciences Inc$71.5M5.21%774,227CommonSOLE
00287Y109ABBVAbbVie Inc$63.9M4.65%359,393CommonSOLE
G50871105JAZZJazz Pharmaceuticals PLC$62.1M4.52%504,193CommonSOLE
803607100SRPTSarepta Therapeutics Inc$52.1M3.80%428,771CommonSOLE
04272N102AVBPArrivent BioPharma Inc$45.2M3.29%1,696,752CommonSOLE
046353108AZNNAstraZeneca PLC$42.7M3.11%651,344CommonSOLE
863667101SYKStryker Corporation$41.8M3.04%116,005CommonSOLE
05464T104AXSMAxsome Therapeutics Inc$41.6M3.03%491,726CommonSOLE
76029N106REPLReplimune Group Inc$38.1M2.78%3,149,522CommonSOLE
45337C102INCYIncyte Corp$36.2M2.64%524,267CommonSOLE
75383L102RAPPRapport Therapeutics Inc$35.4M2.58%1,995,594CommonSOLE
834203309SLNOSoleno Therapeutics Inc$34.0M2.48%757,248CommonSOLE
101137107BSXBoston Scientific Corp$31.0M2.25%346,571CommonSOLE
45166A102IDYAIDEAYA Biosciences Inc$27.5M2.00%1,069,090CommonSOLE
02043Q107ALNYAlnylam Pharmaceuticals Inc$25.9M1.89%110,157CommonSOLE
G01767105ALKSAlkermes Plc$25.7M1.87%894,266CommonSOLE
26818M108DYNDyne Therapeutics Inc$25.2M1.84%1,071,498CommonSOLE
252131107DXCMDexcom Inc$22.6M1.64%290,210CommonSOLE
76243J105RYTMRhythm Pharmaceuticals Inc$22.2M1.62%397,428CommonSOLE
379577208GMEDGlobus Med Inc$20.2M1.47%244,700CommonSOLE
46120E602ISRGIntuitive Surgical Inc$19.8M1.44%37,896CommonSOLE
457669307INSMInsmed Inc$17.7M1.29%256,281CommonSOLE
984241109YMABUSDY-mAbs Therapeutics Inc$17.2M1.25%2,194,278CommonSOLE
805111101SVRASavara Inc$16.8M1.22%5,471,299CommonSOLE
47103J105JANXJanux Therapeutics Inc$13.6M0.99%253,262CommonSOLE
09077V100BIOABioAge Labs Inc$13.3M0.97%2,304,901CommonSOLE
45790W108Inozyme Pharma Inc$11.9M0.86%4,280,308CommonSOLE
532457108LLYEli Lilly & Co$11.1M0.81%14,364CommonSOLE
28036F105EWTXEdgewise Therapeutics Inc$10.8M0.78%402,773CommonSOLE
N69605108PHVSPharvaris N V$10.7M0.78%560,723CommonSOLE
008064107Aerovate Therapeutics Inc$10.0M0.73%3,758,686CommonSOLE
45332Y109NARIUSDInari Med Inc$9.2M0.67%180,456CommonSOLE
87164F105SNDXSyndax Pharmaceuticals Inc$8.7M0.63%658,627CommonSOLE
05464T104AXSMAxsome Therapeutics Inc$8.5M0.62%100,000CALLSOLE
45720N103INBXInhibrx Biosciences Inc$8.1M0.59%527,190CommonSOLE
45257U108IMNMImmunome Inc$7.9M0.58%746,824CommonSOLE
19240Q201COGTCogent Biosciences Inc$6.4M0.47%823,160CommonSOLE
004468500ACHVAchieve Life Sciences Inc$4.6M0.33%1,306,482CommonSOLE
29479A108ERASErasca Inc$4.5M0.33%1,795,880CommonSOLE
G31249108ESTAEstablishment Labs Hldgs Inc$4.4M0.32%95,305CommonSOLE
05352A100AVTRAvantor Inc$4.2M0.31%200,000CommonSOLE
28176E108EWEdwards Lifesciences Corp$3.0M0.22%40,000CommonSOLE
30063P105EXKExact Sciences Corp$2.9M0.21%52,042CommonSOLE
N44445109IMTXImmatics N.V$2.4M0.18%343,206CommonSOLE
235851102DHRDanaher Corporation$2.3M0.17%10,000CommonSOLE
65343E108NXTCEURNextcure Inc$2.1M0.15%2,671,856CommonSOLE
032724106ANABAnaptysBio Inc$1.8M0.13%132,927CommonSOLE
492327101KROSKeros Therapeutics Inc$1.5M0.11%95,375CommonSOLE
097702104BOLT1EURBolt Biotherapeutics Inc$1.5M0.11%2,754,437CommonSOLE
254604101IRONDisc Medicine Inc$1.4M0.11%22,752CommonSOLE
075887109BDXBecton Dickinson & Co$1.1M0.08%4,951CommonSOLE
92764N102VIRVir Biotechnology Inc$837,7220.06%114,131CommonSOLE
44930G107ICUIICU Med Inc$775,8500.06%5,000CommonSOLE
29337E102ELVNEnliven Therapeutics Inc$765,5630.06%34,025CommonSOLE
45175G108Ikena Oncology Inc$627,4900.05%382,616CommonSOLE
89422G107TVTXTravere Therapeutics Inc$568,1710.04%32,616CommonSOLE
86366E106GPCRStructure Therapeutics Inc$566,5910.04%20,892CommonSOLE
745848101LUNGPulmonx Corp$416,4040.03%61,326CommonSOLE
05370A108RNAGBPAvidity Biosciences Inc$400,9840.03%13,789CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.